Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878608 | 0.95 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10219821 | 0.89 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL4637131 | 0.84 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10219616 | 0.84 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10219746 | 0.83 | PPARG (0.55) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10219598 | 0.82 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL23269717 | 0.82 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL24329835 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10219629 | 0.81 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTPPARD | |
| SCHEMBL10219622 | 0.80 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | NPC1 1742/4885RAB9A 1784/4885SMN1; SMN2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.